STOCK TITAN

BIOMERICA INC - BMRA STOCK NEWS

Welcome to our dedicated news page for BIOMERICA (Ticker: BMRA), a resource for investors and traders seeking the latest updates and insights on BIOMERICA.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BIOMERICA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BIOMERICA's position in the market.

Rhea-AI Summary
Biomerica reports Q1 2024 financial results, with a 16.3% increase in revenues excluding Covid test sales. Company expects profitability with current cash position and forecasted revenue growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
-
Rhea-AI Summary
Biomerica reports financial results for Q1 fiscal 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
-
Rhea-AI Summary
Dubai government approves insurance reimbursement for Biomerica's EZ Detect colorectal disease at-home screening test
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.68%
Tags
none
Rhea-AI Summary
Biomerica appoints Jack Kenny, former CEO of Meridian Bioscience, to its Board of Directors. Meridian Biosciences was acquired for $1.53 billion. Kenny's industry insights will be invaluable in launching inFoods IBS. His leadership at Meridian drove outstanding growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
management
-
Rhea-AI Summary
Biomerica reports fiscal 2023 financial results, with net sales of $5.3M compared to $18.9M in fiscal 2022. Net loss was $7.1M for fiscal 2023. Revenues excluding Covid test sales increased by 15% for fiscal 2023. Successful completion of inFoods IBS pilot program with Gastrointestinal physician group. On track for national launch by Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
CVS Pharmacy begins selling Biomerica's EZ Detect colorectal disease screening test in over 7,000 stores nationwide, projected to be on shelves in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.01%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
BIOMERICA INC

Nasdaq:BMRA

BMRA Rankings

BMRA Stock Data

8.96M
15.59M
7.3%
26.73%
0.4%
Dental Equipment and Supplies Manufacturing
Manufacturing
Link
United States of America
IRVINE

About BMRA

biomerica, inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. the company’s products are designed to enhance health and well-being, while reducing total healthcare costs. biomerica primarily focuses on products for gastrointestinal disease, diabetes and esoteric testing. the biomerica infoods® ibs product identifies patient specific foods that when removed may alleviate an individual's ibs symptoms. this patent pending diagnostic guided therapy is designed to allow for a patient specific guided dietary regimen to improve irritable bowel syndrome (ibs) outcomes. the point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product will be the first for wh